NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MUVON Therapeutics

MUVON Therapeutics

Private
ZurichHealthcare & Life Scienceshttps://www.muvon-therapeutics.com/

Last Round

Grant

Dec 12, 2025

Total Funding Raised

$22.42M

Company Overview

MUVON Therapeutics is a biotechnology company developing a cell therapy platform for the regeneration of skeletal muscle tissue using a patient's own cells, with an initial focus on treating stress urinary incontinence in women.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B2C

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

stress urinary incontinenceregenerative medicineautologous cell therapySUI treatmentskeletal muscle regenerationmuscle precursor cellsclinical-stage biotechMPC therapycell therapy platformMUV_001tissue engineeringpersonalized medicineurologyGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MUVON Therapeutics Comparables

Compare MUVON Therapeutics with similar companies based on industry and business-model similarity.

MUVON Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Innovacell Inc
88%
Cook Group Incorporated
83%
Versameb AG
74%

MUVON Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 12, 2025
Series AMay 31, 2021
AcceleratorApr 1, 2021

Key People

Founding team and executive leadership

Christine Guenther

CTO

Executive Team

Steve Kappenthuler

COO CFO

Executive Team

MUVON Therapeutics Investors

Notable investors and investment history

MUVON Therapeutics investors
InvestorRounds
Wyss ZurichSeries A, Accelerator
InnosuisseGrant
University of ZurichSeries A
Lichtsteiner FoundationSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 6, 2026

    Monthly visitors increased 89% MoM, reaching 3.5K.

  • Nov 8, 2025

    Monthly visitors grew 280% MoM, reaching 1.8K.

MUVON Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MUVON Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MUVON Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersZurich
Employee Range17
Year Founded2020
Last FundingDec 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.